Cardiovascular disease is the leading cause of death, accounting for 600,000 deaths each
year in the United States. In addition, heart failure accounts for 37% of health care spending …

Cardiac hypertrophy can be defined as an increase in heart mass. Pathological cardiac
hypertrophy (heart growth that occurs in settings of disease, eg hypertension) is a key risk …

Heterotrimeric G proteins are key players in transmembrane signaling by coupling a huge
variety of receptors to channel proteins, enzymes, and other effector molecules. Multiple …

In this article we present validation of a real-time RT–PCR method to quantitate mRNA
expression levels of atrial natriuretic peptide and c-fos in anin vitromodel of cardiac …

To study the mechanisms that activate expression of the atrial natriuretic factor (ANF) gene
during pressure-induced hypertrophy, we have developed and characterized an in vivo …

Heart failure is a leading cause of mortality in the United States. As a result of advances in
genetic technology, a molecular basis of heart failure is emerging. 1, 2 This review highlights …

Endothelin (ET) peptides and their receptors are intimately involved in the physiological
control of systemic blood pressure and body Na homeostasis, exerting these effects through …

Cardiac hypertrophy is a major risk factor for heart failure and associated patient morbidity
and mortality. Research investigating the aberrant molecular processes that occur during …

A peptidergic activity produced in endothelial cells that caused coronary vasoconstriction
was described in 1985, 1 and a family of peptides, named the endothelins, was …

The endothelin system consists of two G-protein-coupled receptors, three peptide ligands,
and two activating peptidases. Its pharmacological complexity is reflected by the diverse …